Prevention of heart disease by subcutaneous desferoxamine in patients with thalassaemia major

Australian and New Zealand Journal of Medicine

Volumn 23, Issue 6, 1993, Pages 656-661

  Richardson, M E ^a   Matthews, R N ^b   Alison, J F ^b   Menahem, S ^b   Mitvalsky, J ^b   Byrt, E ^c   Harper, R W ^b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

arrhythmia; cardiomyopathy; compliance; desferrioxamine; Thalassaemia

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD; BLOOD TRANSFUSION; CHILD; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; INFUSION PUMP; LIVER; MALE; METABOLISM; MYOCARDIAL DISEASE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK FACTOR; SIDEROSIS;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; DEFEROXAMINE; ELECTROCARDIOGRAPHY; FEMALE; FERRITIN; HUMAN; INFUSION PUMPS; IRON; LIVER; MALE; MYOCARDIAL DISEASES; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SIDEROSIS;

EID: 0027830410     PISSN: 00048291     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1993.tb04722.x     Document Type: Article

References (26)

1. Longitudinal Study of cardiac function in thalassemia major
2. Late cardiac complications of chronic severe anemia with hemochromatosis
3. Iron in the heart: etiology and clinical significance
4. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major
5. Deferoxamine improves left ventricular function in beta‐thalassemia
6. Correlation between computed tomographic values and liver iron content in thalassemia major with iron overload
7. Recommendations regarding quantitation in M‐mode echocardiography: results of a survey of echocardiographic measurements
8. Continuous subcutaneous administration of deferoxamine in patients with iron overload
9. Prevention of iron loading in transfusion dependent thalassemia
10. Clinical features of thalassemia
11. Survival and desferrioxamine in thalassaemia major
12. Survival and causes of death in thalassemia major
13. Prolonged survival in patients with beta‐thalassemia major treated with deferoxamine
14. Cardiac disease in patients with thalassaemia major
15. Treatment of Coolers anemia
16. Echocardiographic abnormalities in patients with transfusion dependent anemia and secondary myocardial iron deposition
17. The cardiac manifestations of thalassemia major: natural history, noninvasive cardiac diagnostic studies and results of cardiac catheterization
18. Preclinical abnormal segmental cardiac manifestations of thalassemia major in children on transfusion‐chelation therapy: echocardiographic alterations of left ventricular posterior wall contraction and relaxation patterns
19. The left ventricular end‐systolic pressure‐dimension relation in patients with thalassemia major: a new noninvasive method for assessing contractile state
20. Early left ventricular dysfunction and chelation therapy in thalassemia major
21. Detection of early cardiac dysfunction in patients with severe beta thalassemia and chronic iron overload
22. Haemochromatosis presenting as severe cardiac failure in a young adolescent
23. Deferoxamine to improve cardiac function in iron overloaded patients with thalassemia major
24. Rapid removal of excessive iron with daily high dose intravenous chelation therapy
25. Reassessment of the use of deferoxamine B in iron overload